INTRODUCTION
Theophylline is commonly used to treat apnea or facilitate extubation in preterm infants. 1 Because there is no intravenous preparation of theophylline, the drug aminophylline, which is approximately 80% theophylline, is commonly used. Target serum theophylline levels of 7-12 g/ml are often recommended based on the theophylline concentrations needed to obtain a significant reduction in the number of apneic episodes and avoid side effects such as tachycardia. 2 -4 Most pediatric medication dosing references recommend an aminophylline loading dose of 4-6 mg/kg, 5 -8 but the likelihood of achieving the recommended levels with an aminophylline loading dose of 6 mg/kg has been questioned. 9, 10 To date there have been no controlled trials with an appropriate number of patients to determine the optimal aminophylline loading dose that will safely result in recommended serum levels. The purpose of this study was to determine if a loading dose of 8 mg/kg would achieve a serum theophylline level in the range of 7-12 g/ml more frequently than a 6 mg/kg dose without any increase in toxicity.
METHODS
Infants with birth weights 1500 g cared for in the Neonatal Intensive Care Unit at Memorial Hermann Children's Hospital were considered eligible for the study when the clinical staff decided to institute intravenous aminophylline therapy. Infants who had previously received methylxanthines were not eligible. After written parental consent was obtained, infants were randomized to receive a loading dose of either 8 or 6 mg/kg of intravenous aminophylline. Infants were allocated using randomization tables that were not available to the clinicians or investigators and which included stratification by birth weight: <1000 or 1000-1500 g.
A research pharmacist who was not involved in patient management dispensed the loading doses. All infants received a standard aminophylline maintenance dose of 2 mg/kg per dose every 8 hours beginning 8 hours after the loading dose. All dose calculations were based on the most recent body weight. Two serum theophylline levels were obtained. The first level was obtained 8 hours after the loading dose and the second level was collected before the fifth maintenance dose. Serum theophylline levels were determined using fluorescence polarization immunoassay. Clinicians and investigators were blinded to the loading dose the infant received and the serum theophylline level achieved after the loading dose. An independent investigator was notified if any serum theophylline level was in the toxic range (>12 g/ml). Toxicity was assessed by monitoring the infant's heart rate, and by the occurrence of feeding residuals or seizures. In addition, the clinical response of the infant (number of apnea and bradycardia episodes and amount of respiratory support required) was monitored.
OBJECTIVE:
To compare 8 mg / kg and 6 mg / kg loading doses of aminophylline.
STUDY DESIGN:
Sixty -one preterm infants weighing < 1500 g were enrolled once a decision to administer intravenous aminophylline was made. A standard maintenance dose was used. Serum levels of theophylline were drawn 8 hours after the loading dose and before the fifth maintenance dose.
RESULTS:
After the initial loading dose, the 8 mg / kg group achieved recommended serum theophylline levels ( 7 -12 g / ml ) more frequently than the 6 mg / kg group ( 39% vs 3%, p = 0.002 ). Subsequent levels were similar between the groups. There were no increases in side effects with the higher loading dose.
CONCLUSION:
If a clinical decision to start intravenous aminophylline therapy in preterm infants has been made, the use of an 8 mg / kg loading dose appears to be a better and safe way to quickly achieve serum theophylline levels within the recommended range. Original Article
Preliminary data showed that <45% of neonates achieved a therapeutic serum concentration with a 6 mg/kg aminophylline loading dose and approximately 75% of neonates achieved a therapeutic serum concentration with an 8 mg/kg aminophylline loading dose. For this preliminary study non steady-state levels were usually obtained before the third maintenance dose. Based on these results, we calculated a sample size of 48 patients per group to detect an increase in the proportion of neonates reaching the desired therapeutic range from 50% to 75%, with a power of 80% and an alpha error of 0.05. Enrollment of 60 patients per group was planned to allow for potential protocol violations. An interim analysis by an independent investigator was planned after 50% enrollment. The stopping rules for this analysis were designed to achieve an overall p value of <0.05 for the primary outcome after adjustment for the interim analysis. Continuous data were compared using either a ttest or a nonparametric rank test if the t-test assumptions were not met. Categorical variables were compared using the chi-square test.
RESULTS
After the primary outcome was available for 60 patients, the planned interim analysis was performed. Based on the criteria described above, a decision was made to stop enrollment when a p value of 0.002 was obtained in this interim analysis. Of 118 eligible infants during the study period, 55 (47%) were not enrolled in the study due to parental unavailability or refusal/failure to obtain informed consent. One infant was randomized but never received aminophylline therapy and another was enrolled but the loading dose the infant received was not recorded. All of the remaining 61 infants were included in the analysis. The baseline characteristics of the infants in the 8 and 6 mg/kg groups were comparable (Table 1) .
Serum theophylline levels drawn 8 hours after the aminophylline loading dose were significantly higher in infants receiving the 8 vs. the 6 mg/kg dose ( Table 2 ). Almost 40% of the infants receiving the 8 mg/kg dose achieved serum concentrations between 7 and 12 g/ ml compared to 3% of those receiving the 6 mg/kg dose. None of the infants had serum theophylline levels >12 g/ml (Figure 1 ). Theophylline levels drawn before the fifth maintenance dose were not significantly different (Table 2 ). There were no differences between the groups in the proportion of infants with tachycardia, feeding intolerance, or other side effects.
Although we recorded the number of apnea and bradycardia episodes on days 1 and 2 of therapy, this study did not have adequate power to evaluate this outcome. In infants who received aminophylline to facilitate extubation (n=39), there was a trend toward more infants being extubated on day 1 after receiving the higher loading dose. Because of the small sample size, we could not exclude a clinically important difference in these outcomes. A much larger study would be needed to evaluate the potential clinical benefits of reaching a therapeutic serum theophylline level quickly.
DISCUSSION
The long-term safety of treating apnea of prematurity with theophylline has not been clearly established. 11 Nonetheless, theophylline is commonly used to treat apnea or facilitate extubation in preterm infants. 1 Pharmacokinetic studies in preterm infants used aminophylline loading doses ranging from 4 to 11.5 mg/kg. 12 -16 It is difficult to determine the optimal loading dose for neonates with apnea based on these studies, because of the wide ranges of loading doses and resulting serum concentrations, and the small numbers of infants enrolled. Likewise, the goals for the serum theophylline levels were variable ranging from 4 to 14.5 g/ml. Current medication references recommend aminophylline loading doses between 4 and 6 mg/kg and serum levels of 6 to 13 g/ml.
-8
Loading doses of theophylline are given so that therapeutic benefit can be achieved quickly. Using too low a loading dose might result in the need for increased respiratory support if there is a delay in achieving therapeutic levels. However, theophylline may produce symptoms of toxicity if too high a dose is used. Therefore, serum concentrations of theophylline are monitored to limit toxicity while maximizing efficacy. In this study, we showed that an 8 mg/kg loading dose of aminophylline, compared to 6 mg/kg, more often achieved the desired target serum level of 7-12 g/ml. We chose this higher loading dose and range of desired theophylline serum levels for several reasons. Because the average volume of distribution of theophylline in preterm infants is approximately 0.8 l/kg, 17 we expected our 8 mg/kg loading dose to achieve a blood concentration of about 10 g/ml. Nonetheless, the average theophylline level that we achieved with the higher loading dose was below that concentration. This probably reflects the large variability in volume of distribution reported in neonates and differences between studies in gestational and postnatal age of the participants. 14, 17, 18 In a small study, Lagercrantz et al. 16 found that the optimal effect of theophylline for apnea of prematurity was achieved when its plasma concentration was at least 7.25 g/ml. Also, Muttitt et al. reported more than 50% clinical response to theophylline only when a level of about 12.7 g/ml was achieved, although the likelihood of side effects such as tachycardia is much higher above those concentrations.
2,4 Therefore, we chose such concentrations as the lower and upper boundaries of our target range.
The higher loading dose was more effective in reaching a therapeutic level without increasing side effects or toxicity. In fact, none of the infants enrolled achieved serum theophylline levels above 12 g/ml at anytime during the study period. Nonetheless, there was still a significant proportion of infants that did not reach the desired range of theophylline levels. Higher loading or maintenance doses may be necessary to reach such levels. Quickly achieving a therapeutic serum theophylline level may have a clinically significant impact on respiratory support requirements and number of apnea and bradycardia episodes; however, our study was not designed to test this hypothesis. Based on the mean and standard deviation for the number of apnea episodes on day 2 of therapy in each group, we calculated that a much larger study with an approximate enrollment of over 250 patients per group would be needed to detect a 25% reduction in apnea episodes with a power of 80%. This larger study could then evaluate the potential clinical benefits of reaching a therapeutic serum theophylline level quickly.
If a clinical decision to use aminophylline with a target blood level of 7-12 g/ml is made, our findings support the use of an initial loading dose of 8 mg/kg of this methylxanthine in preterm infants. This dose seems to be more effective in reaching that goal without an increase in side effects. 
